A Pan-Cancer Analysis of the Oncogenic Role of Insulin-Like Growth Factor2 mRNA -Binding Protein 2 (IGF2BP2) in Human Tumors

Abstract

N6-methyladenosine (m6A) is one of the most common post-transcriptional modifications of eukaryotic mRNA, accounting for approximately 80% of RNA methylation modifications. Increasing studies have demonstrated that m6A modification has an important role in the development of a variety of tumors. Insulin-like growth factor 2 (IGF2BP2), as an important methylation recognition proteins in the process of m6A modification, is similarly involved in the progression of human cancers. Therefore, based on The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets, we first explored the potential oncogenic role of IGF2BP2 in thirty-three tumors and found that IGF2BP2 was highly expressed in most cancers, and it is also strongly associated with poor prognosis in some tumor patients. We performed the first pan-cancer analysis of the m6A methylation recognition protein IGF2BP2with the main goal of gaining a more comprehensive understanding of the oncogenic role of IGF2BP2 in different tumors.